Myriad Genetics MyRisk Hereditary Cancer Test is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status and personal cancer family history, Myriad MyRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing.
At Myriad, we understand the importance of getting an accurate answer. We invest heavily in new technologies and techniques to make sure we minimize the potential for error.
Identifying cancer at an earlier stage provides you important information to better treat your patients and prevent secondary cancers.
Not only will the testing process be painless, the cost of the test is also painless with Myriad. The Myriad Promise is our commitment to provide patients with accurate and affordable genetic results.
MyRisk testing is for both women and men. If a patient has a personal or family history of cancer, hereditary cancer testing is the only way to determine if that patient has hereditary, familial or general population risk of developing a future cancer. Individuals with familial or hereditary cancer risk have a much greater chance of developing cancer during their lifetime.
Testing is quick and easy. If you recommend hereditary cancer testing for a patient, it can be done in your practice. Your staff will first collect a blood or saliva sample from the patient using a special kit, which will be shipped to Myriad for analysis. The patient’s test results will then be mailed to your practice or can be found online through your MyriadPro® account within approximately 2 weeks. The results will give you and your patient valuable information to use to create a personalized plan to potentially prevent cancer, identify cancer at an earlier, more treatable stage or prevent a secondary cancer from occurring.
Myriad offers RNA analysis to all patients with an eligible variant of unknown significance (VUS) after MyRisk testing is complete. Myriad will notify the healthcare provider when RNA analysis could help classify variants, giving providers and patients access to this valuable tool regardless of when, where or how their MyRisk test was submitted.
© 2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.